<DOC>
	<DOC>NCT02688868</DOC>
	<brief_summary>The purpose of this study is to evalute the clinical safety and effectiveness of released specification (2.25mm) of FirehawkTM Sirolimus target-eluting coronary stent system.</brief_summary>
	<brief_title>Evaluation of New Specifications (2.25mm) of FirehawkTM in the Treatment of Coronary Heart Disease ( Firehawk_2.25 )</brief_title>
	<detailed_description />
	<mesh_term>Heart Diseases</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<criteria>1. 1880 years of age, males or nonpregnant women; 2. Evidence of silent ischemia, stability or in patients with old myocardial infarction or unstable angina; 3. Primary target lesion, in situ coronary artery disease; 4. Target lesion length ≤ 60mm, target lesion diameter 2.75mm or 4.0mm (Visual method); 5. The target lesion diameter stenosis ≥ 70% (Visual method); 6. Each target lesion implantation the same stent (Firehawk stand); 7. With indications for coronary artery bypass surgery; 8. To understand the purpose of testing, voluntary and informed consent, patients undergoing invasive imaging followup. 1. Within 1 month of any acute myocardial infarction; 2. Chronic total occlusion (TIMI grade 0 flow before surgery), left main coronary artery disease, mouth lesions, multiplevessel lesions, branch diameter ≥ 2.5mm bifurcation lesions and vascular lesions of the bridge; 3. Severe calcified lesions that cannot be successfully expanded and distorting lesions not suitable for stent delivery; 4. Instent Restenosis lesions; 5. Intracoronary implantation of any branding stents within 1 year; 6. Severe congestive heart failure (NYHA class III and above) ,left ventricular ejection fraction or &lt;40% (ultrasound or left ventricular angiography); 7. Preoperative renal function serum creatinine &gt;2.0mg/DL; 8. Bleeding, active gastrointestinal ulcers, brain hemorrhage or subarachnoid hemorrhage and half year history of ischemic stroke, antiplatelet agents and would not allow an anticoagulant therapy contraindications patients undergoing antithrombotic therapy; 9. Aspirin, clopidogrel, heparin, contrast agent, poly lactic acid polymer and rapamycin allergies; 10. The patient's life expectancy is less than 12 months; 11. Top participated in other drug or medical device and does not meet the primary study endpoint in clinical trials time frame; 12. Researchers determine patient compliance is poor, unable to complete the study in accordance with the requirements; 13. Heart transplantation patients.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>January 2015</verification_date>
</DOC>